Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2025British Journal of HaematologyOpen Access

CD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia

View Full Paper
Ask AI
Bookmark
Share

Authors

ADAlexandra DreyzinNational Institutes of HealthNHNoa G. HoltzmanNational Institutes of HealthCBChallice L. BonifantJohns Hopkins University

Discussion

Loading...

Member takes

Implication

Review assesses clinical outcomes of CD123-targeting therapies in AML, indicating challenges in efficacy and toxicity.

Key Points

  • MAIN FINDING: CD123-targeting immunotherapies show variable anti-tumor responses in acute myeloid leukaemia (AML).
  • KEY EVIDENCE: Clinical outcomes of monoclonal antibodies, CAR T cells, and other therapies were reviewed, revealing mixed results.
  • APPROACH: The review discusses various targeting strategies and preclinical developments aimed at improving treatment outcomes for AML.
  • SIGNIFICANCE: Understanding challenges in therapy efficacy and toxicity can inform future clinical strategies for AML treatment.

Cite This Study

Dreyzin et al. (2025) studied this question.

synapsesocial.com/papers/689a0933e6551bb0af8ce580https://doi.org/10.1111/bjh.70019
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)2022 · 73 citations
  2. 2First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse2014 · 63 citations
  3. 3Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells2017 · 113 citations
  4. 4CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial2020 · 427 citations
  5. 5CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial2025 · 19 citations